Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for WUCT aggregates regulatory documents tied to ETRACS Whitney US Critical Technologies ETNs issued by UBS AG, a foreign private issuer. The core filings here are Forms 6-K, which provide interim financial and legal updates that are incorporated by reference into UBS AG’s Form F-3 registration statement for securities offerings.
In these Form 6-K reports, UBS AG discloses consolidated capitalization in US dollars under IFRS Accounting Standards, detailing short-term and long-term debt issued by UBS AG and its subsidiaries, funding from UBS Group AG, equity attributable to shareholders and non-controlling interests, and total capitalization. Such information helps investors understand the broader balance sheet context of the issuer behind the WUCT-linked ETNs.
The filings also explain how specific 6-K reports are incorporated into UBS AG’s Form F-3 registration statement and any outstanding prospectuses or offering circulars that reference those 6-Ks. This structure means that updates filed on Form 6-K become part of the official documentation for securities, including the ETRACS Whitney US Critical Technologies ETNs associated with WUCT.
Another Form 6-K on this page consists of the opinion of Homburger AG, acting as special Swiss counsel to UBS AG, which is filed as an exhibit to the Form F-3 registration statement and replaces a prior opinion. This highlights the role of legal opinions in UBS AG’s securities registration process.
On Stock Titan, users can access these filings in one place, with AI-powered tools available to summarize key sections, highlight important capitalization and legal disclosures, and help interpret how each new Form 6-K or related document fits into UBS AG’s overall reporting framework for the WUCT-linked ETNs.
UBS AG London Branch is offering $16.74 million of Contingent Income Auto-Callable Securities linked to the common stock of Wells Fargo & Company (WFC). The notes price on 20 June 2025, settle on 25 June 2025 and mature on 23 June 2028, unless called earlier. Each security has a $1,000 stated principal amount and pays a contingent coupon of $26.625 per period, equivalent to 10.65% p.a., only if the closing price of WFC on the relevant determination date is at or above the Downside Threshold Level of $52.78 (70% of the initial price).
Early Redemption mechanics: If on any of the 11 quarterly determination dates prior to maturity the WFC closing price is at or above the Call Threshold Level of $75.40 (100% of the initial price), UBS will redeem the notes at par plus the accrued contingent payment, delivering cash only. If not called, the notes remain outstanding and investors may or may not receive contingent payments depending on WFC’s performance.
Payment at Maturity:
- If the final WFC price on 20 June 2028 is ≥ $52.78, investors receive (i) the $1,000 principal plus (ii) the final contingent coupon.
- If the final price is < $52.78, investors receive the Cash Value, defined as the exchange ratio (1,000 / $75.40 = 13.2621) multiplied by the final price, resulting in a proportional loss of principal that could reach 100% in a severe decline.
Key economic terms
- Aggregate principal: $16,740,000
- Issue price: 100% of par; proceeds to issuer 97.75% after a total 2.25% distribution fee (1.75% sales commission, 0.50% structuring fee)
- Estimated initial value: $967.90 (96.79% of issue price), calculated using UBS internal models and funding curve
- CUSIP/ISIN: 90308VZ95 / US90308VZ951
- Listing: None; secondary trading will be negotiated and may be limited
Risk highlights
- Principal is not protected; investors are fully exposed to downside below the 70% threshold.
- Contingent coupons are not guaranteed; no payment is made for any period in which WFC closes below $52.78.
- The notes are unsecured, unsubordinated obligations of UBS AG and subject to its credit risk.
- Liquidity risk: the securities will not be listed on any exchange.
- Valuation risk: secondary market prices may differ materially from the estimated initial value and may be affected by dealer spreads and market factors.
Investors should review the accompanying February 6 2025 prospectus and product supplement, as well as the “Risk Factors” section beginning on page 9 of this pricing supplement, before investing.